Information  X 
Enter a valid email address

Hemogenyx Pharma Plc (HEMO)

  Print      Mail a friend

Wednesday 15 November, 2017

Hemogenyx Pharma Plc

Directorate Change

RNS Number : 5017W
Hemogenyx Pharmaceuticals PLC
15 November 2017

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")


Directorate change


Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that following the successful completion of the Company's readmission and trading on the main market of the London Stock Exchange, Timothy Le Druillenec, Finance Director, has advised the Board of his intention to step down as a Director at the end of the month and will not be seeking re-election at the forthcoming annual general meeting of the Company in order to pursue other interests.


Timothy was previously Chief Financial Officer of Silver Falcon plc and the Board is in process of putting in place appropriate arrangements for the future financial management of the Company.


Dr Robin Campbell, Chairman of Hemogenyx, commented: "I would like to thank Timothy for his contribution to the Company, and in particular his support during the successful acquisition of Hemogenyx and our listing on the London Stock Exchange."




Hemogenyx Pharmaceuticals Limited

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Dr Robin Campbell, Chairman

Optiva Securities Ltd

Tel: +44 (0)20 3137 1902

Christian Dennis 

Shard Capital Partners LLP

Tel: +44 (0)20 7186 9950

Damon Heath, Erik Woolgar

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams/Duncan Vasey

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893


About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit



This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t